Compass Therapeutics (NASDAQ:CMPX) Stock Price Target Lowered at Wedbush

Compass Therapeutics (NASDAQ:CMPX) had its price objective dropped by research analysts at Wedbush from $1.00 to $0.90 in a report issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Wedbush‘s price objective would suggest a potential upside of 3.09% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Citizens Jmp lowered their price objective on Compass Therapeutics to $4.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 23rd. Piper Sandler raised their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.99.

Compass Therapeutics Trading Up 4.3%

Shares of CMPX stock traded up $0.04 on Tuesday, reaching $0.87. The company’s stock had a trading volume of 531,937 shares, compared to its average volume of 4,512,036. The stock’s fifty day simple moving average is $1.26 and its 200-day simple moving average is $3.08. Compass Therapeutics has a 1 year low of $0.67 and a 1 year high of $6.88. The company has a market capitalization of $157.22 million, a price-to-earnings ratio of -2.17 and a beta of 1.06.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Equities research analysts forecast that Compass Therapeutics will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Fisher Asset Management LLC grew its stake in Compass Therapeutics by 39.8% in the third quarter. Fisher Asset Management LLC now owns 1,945,821 shares of the company’s stock valued at $2,024,000 after purchasing an additional 553,931 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Compass Therapeutics by 88.3% in the third quarter. Russell Investments Group Ltd. now owns 95,084 shares of the company’s stock worth $99,000 after purchasing an additional 44,579 shares in the last quarter. Alps Advisors Inc. raised its holdings in Compass Therapeutics by 29.6% in the third quarter. Alps Advisors Inc. now owns 236,892 shares of the company’s stock worth $246,000 after purchasing an additional 54,115 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of Compass Therapeutics during the third quarter valued at about $104,000. Finally, Sequoia Financial Advisors LLC lifted its position in shares of Compass Therapeutics by 189.5% during the second quarter. Sequoia Financial Advisors LLC now owns 44,980 shares of the company’s stock valued at $99,000 after buying an additional 29,445 shares during the last quarter. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.